PTC Therapeutics, Inc.
PTCT
Pozycja w akcjach
#3483
PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the... PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized therapies and a variety of experimental drug candidates, spanning all stages of development—from early research and preclinical studies to clinical trials—with a primary focus on addressing various rare disease indications. Among its commercialized products, PTC Therapeutics provides Translarna and Emflaza, offering therapeutic options for Duchenne muscular dystrophy patients in the European Economic Area and the United States. Translarna also addresses nonsense mutation Duchenne muscular dystrophy in Brazil and Russia. The company additionally commercializes Tegsedi and Waylivra for various rare conditions throughout Latin America and the Caribbean. Furthermore, in Brazil, PTC Therapeutics distributes Evrysdi as a treatment for spinal muscular atrophy (SMA) in patients aged two months and older. Leveraging its proprietary splicing platform, the company is also actively developing PTC518, a promising therapeutic candidate aimed at treating Huntington's disease. To bolster its research and development capabilities, PTC Therapeutics has established strategic collaborations, including partnerships with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation, focusing on advancing drug discovery and development research, particularly in regenerative medicine. Additionally, it collaborates with Akcea Therapeutics, Inc. for the commercialization of Tegsedi and Waylivra in the Latin America and Caribbean region. Established in 1998, PTC Therapeutics, Inc. maintains its corporate headquarters in South Plainfield, New Jersey.
Cena akcji
$59.28
Ostatnia synchronizacja: 2026-10-16
Kapitalizacja rynkowa
$4.95B
Zmiana (1 dzień)
-2.80%
Zmiana (1 rok)
-10.11%
Kraj
US
Handel PTC Therapeutics, Inc. (PTCT)
Kategoria
Healthcare
Marża operacyjna dla PTC Therapeutics, Inc. (PTCT)
Marża operacyjna na dzień October 2026 TTM: 11.52%
Według najnowszych raportów finansowych i ceny akcji PTC Therapeutics, Inc., bieżąca marża operacyjna (TTM) wynosi 11.52%. Na koniec 2023 wynosiła -37.26%.
Historia marży operacyjnej dla PTC Therapeutics, Inc. od 2011 do 2026
Marża operacyjna na koniec każdego roku
| Rok | Marża operacyjna | Zmień |
|---|---|---|
| 2026 (TTM) | 11.52% | -130.72% |
| 2024 | -37.50% | 0.64% |
| 2023 | -37.26% | -40.81% |
| 2022 | -62.95% | -9.58% |
| 2021 | -69.62% | -38.60% |
| 2020 | -113.39% | 80.56% |
| 2019 | -62.80% | 43.71% |
| 2018 | -43.70% | 32.14% |
| 2017 | -33.07% | -79.29% |
| 2016 | -159.67% | -64.88% |
| 2015 | -454.58% | 5.00% |
| 2014 | -432.93% | 198.74% |
| 2013 | -144.92% | 55.58% |
| 2012 | -93.15% | -401.46% |
| 2011 | 30.90% | 0.00% |
Marża operacyjna dla podobnych firm lub konkurentów
| Firma | Marża operacyjna | Różnica w marży operacyjnej | Kraj |
|---|---|---|---|
| 38.59% | -96.65% |
US
|
|
| -149.01% | -112.93% |
US
|
|
| 25.57% | -97.78% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -97.50% |
NL
|
Czym jest marża operacyjna firmy?
Marża operacyjna to kluczowy wskaźnik do oceny rentowności firmy. Wyższe marże operacyjne są zazwyczaj korzystniejsze, ponieważ pokazują, że firma może sprzedawać swoje produkty lub usługi znacznie drożej niż koszty ich produkcji. Oblicza się ją, dzieląc zysk firmy przez jej przychody.